Stricter requirements on the therapeutic benefit, labelling and manufacturing processes should be set for drug products manufactured by pharmacies on a semi-industrial scale. In the Netherlands only drug products authorized by the Dutch Medicines Evaluation Board or the European Medicines Agency may be sold. In exceptional cases, pharmacies are allowed to manufacture drug products for their own patients. As the volume of manufacturing by pharmacies is decreasing, along with the availability of sufficient experience and suitable equipment in the pharmacies themselves, more and more pharmacies are now turning to dispensing drug products that have been manufactured in other pharmacies, often manufactured on larger scales than is usual for phar...
The modern pharmaceutical industry is a strictly controlled area. Both national and international ru...
International audienceBackground : Good Manufacturing Practice (GMP) guidelines established by the E...
In Nederland mogen alleen geregistreerde geneesmiddelen in de handel worden gebracht, wat wil zeggen...
Stricter requirements on the therapeutic benefit, labelling and manufacturing processes should be se...
Dit rapport bevat een erratum op pag 2Er moeten strengere eisen gesteld worden aan semi-industriele ...
Introduction and objective In the Netherlands, preparing and distributing pharmacies (PDPs) are taki...
Introduction and objective The preparation of medicines in pharmacies is essential for accommodating...
Background: To date there exist no internationally recognised Good Manufacturing Practices (GMP) th...
Introduction The rights of patients should be sufficiently protected even when an appropriate author...
There are no important regulatory barriers obstructing or delaying the registration of new medicines...
Objective: Recently the Laboratory of Dutch Pharmacists (LNA) published a guideline (LNA-procedure P...
Introduction and objective The regulation of pharmacy preparations, especially for standards for qua...
There are no important regulatory barriers obstructing or delaying the registration of new medicines...
Background. Cross-contamination and mix-ups arc among the problems which could have a negative impac...
The modern pharmaceutical industry is a strictly controlled area. Both national and international ru...
International audienceBackground : Good Manufacturing Practice (GMP) guidelines established by the E...
In Nederland mogen alleen geregistreerde geneesmiddelen in de handel worden gebracht, wat wil zeggen...
Stricter requirements on the therapeutic benefit, labelling and manufacturing processes should be se...
Dit rapport bevat een erratum op pag 2Er moeten strengere eisen gesteld worden aan semi-industriele ...
Introduction and objective In the Netherlands, preparing and distributing pharmacies (PDPs) are taki...
Introduction and objective The preparation of medicines in pharmacies is essential for accommodating...
Background: To date there exist no internationally recognised Good Manufacturing Practices (GMP) th...
Introduction The rights of patients should be sufficiently protected even when an appropriate author...
There are no important regulatory barriers obstructing or delaying the registration of new medicines...
Objective: Recently the Laboratory of Dutch Pharmacists (LNA) published a guideline (LNA-procedure P...
Introduction and objective The regulation of pharmacy preparations, especially for standards for qua...
There are no important regulatory barriers obstructing or delaying the registration of new medicines...
Background. Cross-contamination and mix-ups arc among the problems which could have a negative impac...
The modern pharmaceutical industry is a strictly controlled area. Both national and international ru...
International audienceBackground : Good Manufacturing Practice (GMP) guidelines established by the E...
In Nederland mogen alleen geregistreerde geneesmiddelen in de handel worden gebracht, wat wil zeggen...